Cleared Traditional

K081104 - AESKULISA ANA HEP-2, REF 30-7115US

K081104 is an FDA 510(k) clearance for AESKULISA ANA HEP-2, manufactured by Aesku Diagnostics. The device is a Class 2 Immunology device with product code LKJ cleared through the Traditional 510(k) pathway after a 14-day FDA review.

K081104 · Aesku Diagnostics · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
May 2008
Decision
14d
Days
Class 2
Risk

K081104 is an FDA 510(k) clearance for the AESKULISA ANA HEP-2, REF 30-7115US. Classified as Antinuclear Antibody, Antigen, Control (product code LKJ), Class II - Special Controls.

Submitted by Aesku Diagnostics (Wendelsheim, Rheinland, DE). The FDA issued a Cleared decision on May 2, 2008 after a review of 14 days - a notably fast clearance cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5100 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Aesku Diagnostics devices

FDA 510(k) Submission Details - K081104

510(k) Number K081104 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received April 18, 2008
Decision Date May 02, 2008
Days to Decision 14 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary Statement
Third-party Review Yes - reviewed by an FDA-accredited third party
Regulatory Context
Review time vs. panel average
90d faster than avg
Panel avg: 104d · This submission: 14d
Pathway characteristics
Predicate-based equivalence. No clinical trials required. Third-party reviewed.

LKJ Device Classification - Class 2, Special Controls

Product Code LKJ Antinuclear Antibody, Antigen, Control
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5100
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - LKJ Antinuclear Antibody, Antigen, Control

All 37
Devices cleared under the same product code (LKJ) and FDA review panel - the closest regulatory comparables to K081104.
EliA Ro52, EliA Ro60
K210902 · Phadia AB · Jul 2022
ANA-SCREEN WITH MDSS
K113610 · Bio-Rad Laboratories · Jul 2012
ELIA CENP IMMUNOASSAY, ELIA U1RNP IMMUNOASSAY, ELIA SM IMMUNOASSAY, ELIA RO IMMUNOASSAY
K082759 · Phadia US, Inc. · Apr 2009
BIOPLEX 200 ANA SCREEN ON THE BIOPLEX 2200 MULTI-ANALYTE DETECTION SYSTEM, MODEL BIOPLEX 2200
K041658 · Bio-Rad Laboratories, Inc. · Dec 2004
ATHENA MULTI-LYTE ANA-II TEST SYSTEM
K042416 · Zeus Scientific, Inc. · Oct 2004
REAADS DSDNA QUANTITATIVE TEST KIT, MODEL 022-001
K034013 · Corgenix, Inc. · Jan 2004